|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.120 USD | -.--% |
|
-.--% | -22.76% |
| 10/06 | AB Science presents new data on Masitinib |  |
| 18/05 | AB Science S.A. announced that it has received $2.989368 million in funding | CI |
| Market Cap | 68.12M 78.79M 62.78M 58.77M 110M 7.5B 112M 744M 289M 3.65B 296M 289M 12.63B | P/E Ratio 2025 * |
-
| P/E Ratio 2026 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 68.12M 78.79M 62.78M 58.77M 110M 7.5B 112M 744M 289M 3.65B 296M 289M 12.63B | EV / Sales 2025 |
95.4x | EV / Sales 2026 * | 56.8x |
| Free-Float |
67.54% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: AB Science
| 3 months | -22.76% | ||
| 6 months | -11.81% | ||
| Current year | -22.76% |
| 1 month | 1.12 |  | 1.12 |
| Current year | 1.12 | | 1.37 |
| 1 year | 1.12 | | 1.45 |
| 3 years | 0 | | 4.46 |
| 5 years | 0 | | 18.78 |
| 10 years | 0 | | 26.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 11/07/2001 |
Laurent Guy
DFI | Director of Finance/CFO | - | 20/11/2009 |
| Chief Tech/Sci/R&D Officer | - | 01/04/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Alain Moussy
CHM | Chairman | - | 11/07/2001 |
Patrick Moussy
BRD | Director/Board Member | - | 20/09/2011 |
| Director/Board Member | 64 | 27/06/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 78.32M | |
| -1.59% | -4.48% | +14.87% | -20.94% | 67.84B | |
| -1.74% | -2.93% | +29.06% | +104.65% | 8.39B | |
| -1.15% | +4.39% | -3.11% | -11.24% | 7.92B | |
| -0.68% | -2.87% | -5.69% | +18.94% | 4.53B | |
| +1.05% | -3.62% | -27.99% | +34.21% | 3.72B | |
| +2.01% | +12.02% | -14.93% | +4.20% | 3.28B | |
| -2.50% | -0.65% | +33.97% | +27.54% | 2.64B | |
| +3.11% | +2.02% | +1.12% | -18.58% | 1.91B | |
| +1.99% | -1.80% | -20.75% | -22.78% | 1.69B | |
| Average | +0.05% | +3.29% | +0.73% | +12.89% | 11.33B | |
| Weighted average by Cap. | -1.19% | -0.65% | +10.85% | -3.98% |
| 2025 | 2026 * | |
|---|---|---|
| Net sales | 1.1M 1.27M 1.01M 949K 1.78M 121M 1.81M 12.02M 4.67M 58.87M 4.77M 4.67M 204M | 1.2M 1.39M 1.11M 1.04M 1.94M 132M 1.97M 13.11M 5.09M 64.22M 5.21M 5.1M 222M |
| Net income | - | - |
| Net Debt | - | - |
Employees
36
Sector
Pharmaceuticals
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AB Stock
- ABSC.F Stock
Select your edition
All financial news and data tailored to specific country editions
